Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes

View at publisher Summarise with VIRAT
Authors: Giovanna Liuzzo, Carlo Patrono
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This comment refers to ‘Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes’ which was published in the New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2505928. Over the past decade, incretin-based therapies have reshaped cardiovascular risk management in type 2 diabetes. Large cardiovascular outcome trials have consistently demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events, largely driven by effects on ASCVD outcomes rather than HF.2–5 Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, showed unprecedented efficacy on glycaemic control and body weight, raising expectations that these metabolic advantages - might translate into incremental cardiovascular benefits beyond - those achieved with GLP-1RAs.6–8 The SURPASS-CVOT trial was therefore designed to rigorously test the cardiovascular safety and potential superiority of tirzepatide vs dulaglutide in patients with type 2 diabetes and established ASCVD. A major strength of this study lies in its conservative and methodologically robust design. The trial adopted a particularly stringent non-inferiority margin, with the upper limit of the 95.3% CI of the HR set at 1.05. This narrow margin substantially reduces the risk that a clinically meaningful loss in cardiovascular efficacy could be missed. In addition, the study employed a standard three-component primary endpoint—cardiovascular death, MI, or stroke—consistent with contemporary cardiovascular outcome trials, facilitating comparisons with prior GLP-1RA studies. The trial was adequately powered to detect realistic differences in efficacy, assuming a 10% lower risk for non-inferiority and a 15% lower risk for superiority. Follow-up extended to approximately four years, and event accrual was appropriate: the annualized event rate in the dulaglutide group (3.3%) was only marginally lower than anticipated, confirming effective population risk enrichment.

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Heart Failure Treatment and Management

Publication details

Journal / source
European Heart Journal
Volume
47
Issue
24
Pages
3225–3226
Publication date
25 March 2026
Language
EN